IVIM & OLINK in Sarcoma (NCT05950594)
Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas
🩺 Plain-English Summary (8th-Grade Level)
The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).
Who can join: Review the eligibility criteria below.
Location: University Health Network — Toronto, Ontario
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
- Radiotherapy (RADIATION)
- Surgery (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University Health Network — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 946-4501
Email: david.shultz@rmp.uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Soft Tissue Sarcoma
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma — St Louis, Missouri
- Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs — Basking Ridge, New Jersey
- Hypofractionated Radiotherapy for Soft Tissue Sarcomas — Madison, Wisconsin
- TVEC and Preop Radiation for Sarcoma (8 ml Dose) — Iowa City, Iowa
- Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma — Philadelphia, Pennsylvania
- A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma — Houston, Texas
Explore by condition: All Soft Tissue Sarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.